TX-MARY-KAY
13.1.2022 14:05:07 CET | Business Wire | Press release
Mary Kay Inc., one of the world’s innovative skincare companies, participated at two renowned European conferences in late 2021. At the 19th Aesthetic & Anti-Aging Medicine World Congress, Mary Kay Inc. submitted a scientific poster on the usage and tolerability of a highly concentrated retinol formula in Asian skin. Mary Kay Inc. also partnered with the European Society’s Dermatological Research (ESDR) in sponsoring Future Leaders in Dermatology Symposium at their 50th Annual conference. At this conference, Mary Kay Inc. shared the results of a recent clinical study that demonstrated the capability of a cosmetic formulation to alleviate symptoms associated with sensitive skin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005071/en/
The 19th Aesthetic & Anti-Aging Medicine World Congress took place from September 16-18, 2021, in Monte Carlo and was held under the High Patronage of H.S.H. Prince Albert II of Monaco. Attendees of this conference extended to several professions including dermatologists, plastic and cosmetic surgeons, anti-aging doctors, and aesthetic and general practitioners. Over 8,300 participants from 130 countries joined the conference, both in-person and virtually. The digital platform offered an immersive virtual experience that complemented the physical show allowing attendees to join the digital exhibition and watch workshops regardless of the distance or travel restrictions.
Mary Kay scientists were proud to share their latest research on retinol use and tolerability at this conference. By using a gradual retinization protocol on Asian individuals, there was an improvement in their overall skin appearance as well as a reduction in post-inflammatory hyperpigmentation - a common concern when using retinol, especially in skin of color.
“Retinol is a gold-standard skincare ingredient with many proven benefits, but the experience and tolerability of a retinol product are not the same for every person. For individuals who are concerned about potential irritation or hyperpigmentation, the results of this study offer potential solutions. I am very excited to share this research with the scientific community worldwide at AMWC’s 19th World Congress to share our innovative research with professionals in skin science and aging,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc.
“AMWC 2021 featured a multi-faceted aesthetic and anti-aging medicine program aimed at promoting high-level continued education and we were happy to have Mary Kay participate this year. We hope that we have succeeded in helping to inspire the exchange of new ideas and the sharing of ‘know-how’ in this field on a global level”, said Catherine Decuyper, EuroMediCom Founder and President. “I am grateful to our team, our global partners, the attendees, and the scientific community at large for their contributions and for the opportunity to serve them and their aesthetic and anti-aging medicine needs.”
Following the success of AMWC 2021, EuroMediCom will host AMWC 2022 from March 31 to April 2, 2022, in a hybrid format again in order to allow delegates from across the world to join them for the 20th edition of their world-leading aesthetic and anti-aging medicine congress. Registrants can choose to attend in person or watch live-streamed sessions from anywhere in the world.
The annual European Society’s Dermatological Research (ESDR) Conference is held in Europe each year every September. In 2021, due to travel restrictions and COVID-19 precautions, the annual meeting took place entirely virtually from September 22-15, 2021. ESDR supports investigative dermatology with the goal of improving the health of patients who are suffering from various skin and infectious diseases and immune disorders. In addition to presenting research, Mary Kay was also able to sponsor a Future Leaders in Dermatology symposium that kicked off the conference.
Associate Principal Scientist Geetha Kalahasti at Mary Kay Inc. shared the results of a recent clinical study that evaluated the effects of a new formulation that contained a blend of lipids identical to the skin's natural ratio, a nociceptor (TRPV-1) antagonist, and a botanical extract that reduces the expression of proinflammatory cytokines.
“At Mary Kay, we are committed to understanding skin biology and designing new products that address skin needs. One ongoing area of focus has been the relationship between sensitive skin and skin barrier function,” said Kalahasti. “Each of these materials targeted a specific biological pathway that contributes to skin redness. The findings revealed that this multi-faceted approach helps strengthen the compromised skin barrier and alleviate discomfort associated with sensitive skin.”
“On behalf of the ESDR board, we would like to thank Mary Kay for the support of the ESDR and the generous contribution to ESDR activities. One of the most important activities of our Society is to promote the presentation of new research data and ideas, and we are delighted to have Mary Kay be a part of this event,” said Leopold Eckhart, Chair, Scientific Program Committee of ESDR.
This particular symposium helps connect young researchers with renowned scientists in dermatology and encourages such collaborations – a focus that is very important to Mary Kay Inc.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn or follow us on Twitter .
ABOUT EUROMEDICOM
EuroMediCom, created in 1999 and part of Informa Exhibitions since 2010, is dedicated to promoting Life Sciences and knowledge through educational Trainings, Conferences & Exhibitions. The main event, AMWC was created in 2003 and has since become the largest and leading medical aesthetic congress in the world. AMWC was developed with the strong belief that external aesthetic treatments and internal aging prevention could be comprehensively addressed by integrating two aspects: aesthetics strategy through dermatology and surgery procedures for external appearance and anti-aging medicine for prevention of aging and enhancement of aesthetic treatments. For more information about AMWC, click here: https://www.euromedicom.com/en/home.html
ABOUT THE EUROPEAN SOCIETY DERMATOLOGICAL RESEARCH (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and towards improving the health of patients suffering from skin and venereal disease, infectious diseases, and immune-mediated and inflammatory disorders. The ESDR facilitates exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release
A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive
Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders15.6.2026 17:30:00 CEST | Press release
For Boomi, this recognition reinforces its vision and momentum in enterprise agentic AI Boomi, the data activation company for AI, today announced it has been recognized as aPioneer in the Gartner® Emerging Market Quadrant for No-Code Agent Builders (NCAB). Gartner defines the NCABs market as SaaS-delivered products that offer an integrated design and runtime environment to build, publish and manage AI-powered agents without using coding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615413216/en/ Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders Boomi sees this recognition as a reflection of the company's rapid evolution from an integration and automation powerhouse to a full-scale agentic infrastructure platform, expanding Boomi’s role in the emerging agentic AI market. A New Chapter in Enterprise Agentic AI According to Gartner, vendors recognized as a Pioneer in this quad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
